Compare BridgeBio Pharma Inc (BBIO) vs Annaly Capital Management, Inc. (NLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Annaly Capital Management, Inc. — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Annaly Capital Management, Inc. trades at $23.23 (market cap $17.27B). The key difference: BridgeBio Pharma Inc and Annaly Capital Management, Inc. are close in size by market cap, and Annaly Capital Management, Inc. pays a 13.09% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | NLY | |
|---|---|---|
Market Cap | $16.61B | $17.27B |
Sector | Health | Financials |
52-Week High | $90.17 | $24.40 |
52-Week Low | $47.29 | $20.21 |
Enterprise Value | $18.16B | — |
Dividend Yield | — | 13.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Annaly Capital Management (NLY) trades at $23.04, up 1.68% today, with a bullish technical outlook and strong earnings momentum after beating Q2 2026 EPS estimates. The stock shows robust fundamentals with a P/E of 5.57, ROE of 20.66%, and a net income margin of 92.77%. Recent news highlights inclusion in Zacks' Strong Buy lists and a focus on high-yield income, supported by a $0.75 dividend payment scheduled for July 2026.
Outlook is positive with analyst consensus favoring Buy ratings (57.15%) and a $24.50 price target, implying ~6% upside. Key risks include interest rate sensitivity and mortgage market volatility, but diversified housing finance strategies and consistent dividend coverage provide stability. Investment appeal centers on value valuation and income generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →
